5.12.3 Russian Biosimilar MAb Revenue Forecast 2013-2023
6. Leading Companies for Biosimilar MAbs, 2013
6.1 Prominent Companies in the Biosimilar Monoclonal Antibodies Industry, 20136.2 Collaboration in Biosimilar MAb Development6.3 BioXpress: 16 Compounds in the R&D Pipeline6.4 Celltrion: One Compound on the Market and Two in Phase III of Development, and Others Wait In The Wings6.5 Harvest Moon: 6 Compounds Under Development6.6 Gene Techno Science: 6 Compounds Under Development6.7 Mabion: Poland's Leading Biosimilar MAb Developer6.8 India's Biocon: A Quiet Competitor6.9 Pfizer: Big Pharma Is Entering the Biosimilar MAb Market6.10 BIOCAD6.11 Big Pharma and the Biosimilar MAbs Market
7. Qualitative Analysis of the Biosimilar MAbs Market, 2013-2023
7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibody Market, 2013
7.1.1 Worldwide Demand for More Affordable Therapies Underpins the Market
7.1.2 The Complexity of the Molecules Engenders a Myriad of Market Weaknesses
7.2 Opportunities and Threats Facing the Biosimilar Monoclonal Antibody Market, 2013-2023
7.2.1 A Well-Stocked Pipeline in the Face of Approaching Patent Expiries: Opportunities for Market Expansion
7.2.2 Competition and Lack of Confidence: Threats to Market Penetration?
220.127.116.11 Biobetters as a Threat to Biosimilars
7.3 Social, Technological, Economic and Political Factors Influencing the Biosimilar Monoclonal Antibodies Market (STEP Analysis) 2013-2023
7.3.1 Social Factors: Driving or Restraining the Market?
7.3.2 Advances in Technology: Producing Biosimilar MAbs Cheaply and Easily
7.3.3 Economic Pressures are Driving the Demand for Biosimilar MAbs
7.3.4 Political Issues: Stringent Regulations are Hurdles to Market Entry
8. Research Interviews
8.1 Interview with Dr '/>"/>
Copyright©2012 PR Newswire.
All rights reserved